170 related articles for article (PubMed ID: 29204180)
1. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.
Mohammadian M; Zeynali S; Azarbaijani AF; Khadem Ansari MH; Kheradmand F
Res Pharm Sci; 2017 Dec; 12(6):517-525. PubMed ID: 29204180
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine.
Mohammadian M; Zeynali-Moghaddam S; Khadem Ansari MH; Rasmi Y; Fathi Azarbayjani A; Kheradmand F
Adv Pharm Bull; 2019 Aug; 9(3):439-444. PubMed ID: 31592113
[No Abstract] [Full Text] [Related]
3. Anti-cancer effects of chemotherapeutic agent; 17-AAG, in combined with gold nanoparticles and irradiation in human colorectal cancer cells.
Moradi Z; Mohammadian M; Saberi H; Ebrahimifar M; Mohammadi Z; Ebrahimpour M; Behrouzkia Z
Daru; 2019 Jun; 27(1):111-119. PubMed ID: 30835081
[TBL] [Abstract][Full Text] [Related]
4. A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Zeynali-Moghaddam S; Mohammadian M; Kheradmand F; Fathi-Azarbayjani A; Rasmi Y; Esna-Ashari O; Malekinejad H
Gene; 2019 Feb; 684():30-38. PubMed ID: 30315927
[TBL] [Abstract][Full Text] [Related]
5. Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.
Ebrahimpour M; Mohammadian M; Pourheydar B; Moradi Z; Behrouzkia Z
J Lasers Med Sci; 2022; 13():e9. PubMed ID: 35996484
[No Abstract] [Full Text] [Related]
6. Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29).
Zeynali-Moghaddam S; Kheradmand F; Gholizadeh-Ghaleh Aziz S; Abroon S
Ann Med Surg (Lond); 2022 Jun; 78():103850. PubMed ID: 35734719
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
8. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
9. HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.
Mohammadi A; Yaghoobi MM; GholamhoseynianNajar A; Kalantari-Khandani B; Sharifi H; Saravani M
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):62-67. PubMed ID: 27894402
[TBL] [Abstract][Full Text] [Related]
10. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Mol Pharmacol; 2004 Jan; 65(1):235-43. PubMed ID: 14722256
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
[TBL] [Abstract][Full Text] [Related]
12. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide.
Flis S; Spłwiński J
Anticancer Res; 2009 Jan; 29(1):435-41. PubMed ID: 19331183
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
15. Honeybee Venom Synergistically Enhances the Cytotoxic Effect of CNS Drugs in HT-29 Colon and MCF-7 Breast Cancer Cell Lines.
Duarte D; Falcão SI; El Mehdi I; Vilas-Boas M; Vale N
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335887
[TBL] [Abstract][Full Text] [Related]
16. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
[TBL] [Abstract][Full Text] [Related]
18. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
20. Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.
Al-Keilani MS; Alsmadi DH; Darweesh RS; Alzoubi KH
Clin Pharmacol; 2018; 10():23-29. PubMed ID: 29551915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
